Vivek Thakur and Shiva Sharma
Vincristine sulphate (VCS) is a vinca alkaloid obtained from the periwinkle plant (Catharanthus roseus) is the most widely recognized chemotherapeutic medications utilized for the treatment of a few types of malignancies. Moreover, VCS is a potent anticancer agent and drug of choice for the treatment of childhood and adult acute lymphocytic leukemia, Hodkin’s and non-Hodgkin’s lymphoma as well as solid tumors including sarcomas, neuroblastoma, breast cancer, etc. In any case, poor biopharmaceutical and pharmacokinetic characteristics of VCS like high dosing recurrence and broad protein binding limit the clinical capability of VCS in tumor treatment. This review focuses on progress in the encapsulation efficiency and sustained release pattern of the drug.